Nasus Pharma Ltd (NSRX)

Currency in USD
3.49
+0.09(+2.65%)
Real-time Data·
NSRX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
3.323.59
52 wk Range
1.989.99
Key Statistics
Prev. Close
3.4
Open
3.55
Day's Range
3.32-3.59
52 wk Range
1.98-9.99
Volume
58.7K
Average Volume (3m)
191.78K
1-Year Change
-
Book Value / Share
0.31
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NSRX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
20.00
Upside
+473.07%
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week

Nasus Pharma Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Sell
Moving Averages
Buy

Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company’s products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.

Employees
7

Compare NSRX to Peers and Sector

Metrics to compare
NSRX
Peers
Sector
Relationship
P/E Ratio
−7.0x−0.4x−0.4x
PEG Ratio
0.030.010.00
Price/Book
14.6x1.4x2.6x
Price / LTM Sales
-2.2x3.2x
Upside (Analyst Target)
-363.4%46.7%
Fair Value Upside
Unlock33.2%7.6%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 20.00
(+473.07% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Citizens
Buy18.00+415.76%19.00Maintain26-03-2026
Citizens
Buy19.00+444.41%-New Coverage18-12-2025

Earnings

Latest Release
25-02-2026
EPS / Forecast
-0.38 / -0.53
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

NSRX Income Statement

FAQ

What Is the Nasus Pharma Market Cap?

As of today, Nasus Pharma market cap is 39.82M.

What Is Nasus Pharma's Earnings Per Share (TTM)?

The Nasus Pharma EPS (TTM) is -0.72.

When Is the Next Nasus Pharma Earnings Date?

Nasus Pharma will release its next earnings report on 03-06-2026.

From a Technical Analysis Perspective, Is NSRX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

What Stock Exchange Does Nasus Pharma Trade On?

Nasus Pharma is listed and trades on the New York Stock Exchange.

What Is the Stock Symbol for Nasus Pharma?

The stock symbol for Nasus Pharma is "NSRX."

How Many Times Has Nasus Pharma Stock Split?

Nasus Pharma has split 0 times.

How Many Employees Does Nasus Pharma Have?

Nasus Pharma has 7 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.